Hims & Hers Health, Inc. (HIMS)
Why Is Hims & Hers Health (HIMS) Up 38% Since Last Earnings Report?
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock?
Hims & Hers Expands Integrated Digital Healthcare Ecosystem
HIMS builds a seamless digital healthcare ecosystem, expanding into diagnostics, global markets and specialty care to reshape access and delivery.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $23.15, indicating a -7.33% shift from the previous trading day.
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market
Hims & Hers Health, Inc. (HIMS) closed at $23.84 in the latest trading session, marking a -7.88% move from the prior day.
Stock Market Today, March 12: Hims and Hers Health Drops After Rally Sparks Profit Taking
Expand NYSE: HIMS Hims & Hers Health Today's Change (-7.75%) $-2.00 Current Price $23.88 Key Data Points Market Cap $5.9B Day's Range $23.77 - $27.20 52wk Range $13.74 - $70.43 Volume 2.1M Avg Vol 30M Gross Margin 60.86%
Hims & Hers Plunges 29.4% in Three Months: How to Play the Stock?
HIMS is navigating margin and regulatory pressure, but new benefits, a Novo Nordisk tie-up and platform growth could drive its next move.
Eli Lilly Stock Slips After Warning on Compounded GLP-1 Drugs With Additives
Shares of Eli Lilly and Company (LLY) slipped about 1% in early Thursday trading after the drugmaker cautioned about potential safety concerns tied to compounde
Is Hims & Hers Really the Growth Stock to Buy That It Appears?
Hims & Hers Health ( NYSE:HIMS ) looked like a fallen growth star earlier this year.
Hims & Hers Health And Novo Nordisk: A Corporate Remarriage That May Work Out Profitably
Hims & Hers Health (HIMS) is rated a Speculative Buy after its renewed partnership with Novo Nordisk, providing legitimate access to lucrative branded GLP-1 therapies. HIMS has demonstrated rapid revenue growth and improving profitability, with gross margins rising from 30% to nearly 75% and operating income turning positive. Valuation appears reasonable given future earnings growth potential, though current multiples are above sector averages on earnings but below on sales.
Hims & Hers: The Novo Nordisk Deal Changes Everything
The Novo Nordisk partnership legitimizes Hims & Hers' business model by replacing compounded GLP-1 sales with branded Wegovy and Ozempic distribution. Hims generated $2.35B revenue in 2025 (+59% YoY) with $318M EBITDA and $300M operating cash flow, demonstrating strong platform economics. The company ended 2025 with 2.5M+ subscribers and $83 average monthly revenue per user, reflecting growing cross-selling across health categories.
This Novo Nordisk Partnership Shows That HIMS Has All The Leverage
Hims & Hers (HIMS) is still a Strong Buy, given that the transformative partnership with Novo Nordisk resolves legal risks and unlocks new growth avenues. HIMS' core value lies in its 2.5M+ cash-pay customer base, enabling leverage with major pharma and supporting expansion into branded drug programs. With the Novo deal, I anticipate 2026 revenue could exceed $3.1B, sustaining 20%+ annual growth through 2029 and materially improving EBITDA margins.
